Open AccessRole of liposome in treatment of overactive bladder and interstitial cystitis
Author(s) -
Shih-Ya Hung,
David D. Chancellor,
Michael B. Chancellor,
YaoChi Chuang
Publication year - 2015
Publication title -
urological science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.155
H-Index - 8
eISSN - 1879-5234
pISSN - 1879-5226
DOI - 10.1016/j.urols.2014.12.008
Subject(s) - overactive bladder , liposome , medicine , interstitial cystitis , urology , urinary bladder , drug delivery , pharmacology , urinary system , pathology , chemistry , biochemistry , alternative medicine , organic chemistry
Intravesical (local) therapy of agents has been effective in delaying or preventing recurrence of superficial bladder cancer. This route of drug administration has also shown tremendous promise in the treatment of interstitial cystitis/painful bladder syndrome (IC/PBS) and overactive bladder without systemic side effects. Liposomes are lipid vesicles composed of phospholipid bilayers surrounding an aqueous core. They can incorporate drug molecules, both hydrophilic and hydrophobic, and show greater uptake into cells via endocytosis. Intravesical liposomes have therapeutic effects on IC/PBS patients, mainly because of their ability to form a protective lipid film on the urothelial surface. Recent studies have shown the sustained efficacy and safety of intravesical instillation of botulinum toxin formulated with liposomes (lipo-BoNT) for the treatment of refractory overactive bladder This review considers the current status of intravesical liposomes or liposomal mediated drug delivery for the treatment of IC/PBS and overactive bladder